Abstract
Background: Patients with liver cirrhosis are at a high risk of drug interactions due to the use of multi-drug combination regimens. Objectives: This study analyzed potential drug-drug interactions in the liver cirrhosis patients at Gatot Soebroto Army Hospital, Jakarta in 2016. Material and Methods: This study employed an observational-cross sectional design with retrospective data collection of liver cirrhosis patients' medical records. The data of potential drug-drug interactions were identified using Drug Interaction Facts 2012 including the mechanism type, the severity and the onset of drug interactions. Results: As many as 88% of the liver cirrhosis patients experienced potential drug-drug interactions with a total of 35 cases. The highest proportions of the cases were found in the pharmacokinetic mechanism by approximately 25 cases (71.43%), minor severity comprising 29 cases (82.86%) and rapid onset by 19 cases (54.29%). The highest potential drug-drug interactions were furosemide-propranolol combination in 16 cases (45.72%). Conclusions: The high incidence of potential drug interactions in patients with liver cirrhosis requires high vigilance and close monitoring of all health professionals in achieving optimal therapeutic outcomes for the patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Jurnal Farmasi Galenika (Galenika Journal of Pharmacy) (e-Journal)
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
